Annovis Bio Inc (ANVS) Quote

JUNK should be the ticker for this company. Horrible performance.

Wait for the final play of this act…..the buyout offer 75% above the 5 yr low.

The dead board is purposefully designed to drive away impatient investors after the hype around the secondaries fades. Nothing the company can say right now can help as trials are ongoing and over promotion is discouraged by gov. agencies.

Dead board. This company needs to start attending investor fairs. They need some interest from institutions.

Dead board. This company needs to start attending investor fairs. They need some interest from institutions.

Companies often schedule investor webcasts when they have positive developments, strategic updates, or milestones to communicate. The presence of the CEO, especially in biotech, usually signals confidence and a controlled narrative. However, it's not a guarantee of good news. Webcasts can also be used to manage expectations, clarify prior results, or preemptively address market concerns.

I was going to sell a couple of days ago when this dropped below $3.00 -- still holding.
Will most likely sell if this goes back to $2.50

Thanks for the info.

Alright I'm changing my view. The price mostly held after the 30% pop earlier this week. I assume that's a good sign. Steady upticks each week from here on would be great! See you at $60

Price rise with no news, huge volume... gotta be either a pump and dump, though I can't find any new articles in the penny stock magazines, or buying by some insider before dilution. Either way we are all sure to get screwed. I took profits today and am out until the dust settles.

The exact same way it closed over $100 with preliminary data. All on hype and manipulation through High Frequency Trading.

The company is nearing a capital raise and big money henchmen never pay top dollar. They always short the stock down, especially low floaters like Anvs, and then get in with their “subscriber” buddies riding the sale of the equity stake up. Wash rinse repeat.

All imho of course

How is the float 19.1M and this is in the dollar range? Seems impossible, right? Also with only 100M in market cap, this doesn't support a successful outlook. Where is the big money at? Sorry, new here, this one is interesting as Phase 3 is underway.

$ANVS: She's been going for a week........ now $1.90

Looking at July 18, 2025 $2.50 Calls are now at $0.16

Possibility this gets to $5/shprice and these calls get to $0.60 if this keeps up


GO $ANVS

Good luck with your investment. I agree they will run this up as dilution occurs as this stock is very thinly traded and if they want control they will force more secondary’s raising the sharecount.

My money instead is on AVXL. They submitted to the EMA for Alzheimers and we should hear something by Nov-Jan if not earlier.

I have 2,500 shares as a lottery ticket. I think there's going to be another run in the near future.

.

Transfer of wealth from the impatient to the patient, just like clockwork. Might be a good entry price.

Secondary into the market? Great price for the shorts who have been faithful.

Yes, I agree -- very slow.
And they're dumping shares for financing.

ANVS, new 52 week low

Watch Out FDA!!!! There is a new Sheriff in town and all your CROOKED DEALS with those Big Pharma's of the world trying to STOP and Destroy new Treatments and or cures before they can begin is coming to an end in my opinion!!!!

I am starting to believe that people have not realized how the confirmation of Robert F. Kennedy Jr truly means for this stock and company.... If anyone was to pay attention to his hearing and some of his pressers of how he specifically mentions Amyloid plaques are a hallmark of Alzheimer's disease and how we need more treatments addressing this issue!!!!

never mind - I see what you meant - phase 3 is starting out slow.

why do you say 2 people? Their website says this:

The study was completed with 345 patients, of which 90 were identified as having mild AD (MMSE 21-24). These 90 AD patients showed dose-dependent, statistically significant improvements from placebo in the two higher concentrations (15mg, p=0.042; 30mg, p=0.015) and all doses showed significant improvement over baseline (7.5mg, p= 0.013; 15mg p=0.001; 30mg p

We hit the bottom last 2 days.

Wow, after all this time...they (just) started phase III. And that's with only 2 people being tested.

Will be Summer until some news comes out.

Stock will be over 100$ some day

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD.

"The launch of our highly anticipated AD study is a significant milestone in advancing buntanetap toward market approval and addressing the unmet medical need of millions of patients. Our previous trials have delivered compelling results, and we have meticulously designed a comprehensive protocol to evaluate both the symptomatic and potential disease-modifying effects of our drug candidate,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis.

The Phase 3 trial is a randomized, placebo-controlled, double-blind study designed to evaluate the safety and efficacy of a daily dose of buntanetap in patients with early AD. The treatment will last for 18 months and will consist of two parts: a 6-month assessment of symptomatic effects followed by an additional 12-month evaluation of buntanetap’s potential disease-modifying effects. This Phase 3 protocol received FDA approval following positive data from our previous Phase 2/3 trial, which demonstrated significant cognitive improvement in a subgroup of patients with early AD and showed no safety concerns.

The Company has recently completed a public offering of 5,250,000 units consisting of one share of our common stock and one warrant to purchase one share of common stock for gross proceeds of $21 million securing the estimated funding for the initial 6-month portion of the study, while the 12-month phase is expected to be supported by additional capital from the warrant exercises.

"Alzheimer’s steals so much from individuals and their families, but with drugs like buntanetap, we aim to restore quality of life and bring hope to those affected. We are grateful to the community for their continuous support and to everyone who has contributed to making this trial a reality. As we embark on this new chapter, we are optimistic that this study will help redefine the future of Alzheimer’s treatment,” adds Melissa Gaines, SVP of Clinical Operations.

The study’s primary outcomes will include the assessment of cognition using the Alzheimer's Disease Assessment Scale-Cognitive 13 (ADAS-Cog13) subscale and functional ability using the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) scale.

Annovis anticipates enrolling over 750 participants across ~100 sites in the United States. The first two open sites that began recruiting include Conquest Research in Winter Park, FL and Advanced Memory Research Institute of New Jersey in Tom’s River, NJ, each managed by the dedicated teams of Malisa Agard, M.D. and Arun Singh, D.O., respectively. Detailed information about the trial is available at clinicaltrials.gov.

About Buntanetap Buntanetap is a small, orally available molecule that targets neurodegeneration by inhibiting the translation of neurotoxic aggregating proteins and thereby impeding the toxic cascade. This improves axonal transport, synaptic transmission, and reduces neuroinflammation, ultimately restoring the health of nerve cells and brain function. By normalizing these pathways, buntanetap has the potential to reverse neurodegeneration and improve quality of life for patients.

About Annovis Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor AlertsInterested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Forward-Looking StatementsThis press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact Information:Annovis Bio Inc.101 Lindenwood DriveSuite 225Malvern, PA 19355www.annovisbio.com

Investor Contact:Scott McGowanInvestorBrandNetwork (IBN)Phone: 310.299.1717www.annovisbio.com/investors-relationsIR@annovisbio.com


Source: Annovis Bio, Inc.

I went ahead and bought 40,153 shares @ $3.47ish today. Now that they've raised $21 Million, I think there is very little downside. The upcoming trial should be exciting.

FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway

MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in January 2025.

In October 2024, the FDA granted clearance for Annovis to proceed with the pivotal Phase 3 AD studies based on its Phase 2/3 data demonstrating cognitive improvement in early-stage AD patients. The original protocol design proposed two separate trials: a 6-month symptomatic study and an 18-month disease-modifying study. Under the revised protocol, these studies are now integrated into a single 6/18-month trial, which will include a 6-month data readout focused on symptomatic effects, followed by an additional 12-month assessment to evaluate the disease-modifying potential of buntanetap.

“This consolidated protocol will accelerate the development timeline while maintaining the scientific rigor necessary to advance buntanetap as a treatment for AD,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. “With this design, we can leverage the 6-month symptomatic data to potentially support a New Drug Application (NDA) filing, all while continuing the same study seamlessly to assess long-term disease-modifying outcomes. We are excited to move forward with this approach, which brings us closer to delivering a novel treatment to patients in need.”

About Annovis Bio

Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.annovisbio.com/email-alerts. Additionally, we invite you to explore our updated investor website, which provides comprehensive access to company news, financial reports, and other key information.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
www.annovisbio.com/investors-relations
IR@annovisbio.com

Let's hope we're both right, Loof, in our reasons for accumulation. $30+ would be good.

This was supposed to be a great PR this morning.

All my hopes in the company has ended.

This went up 64% premarket, and 20 minutes into trading it's in the red by 8%.

The company has become a scam enterprise.

I'll have to agree with you. I watched this hit $8.76 premarket, dumping, then right back down to yesterday's close at $5.35.

HF’s must be licking their lips readying for another round of funding using every market event to further their profit.

I bought 2,000 shares of this one...even though it looks like this might drop lower with the selling.

Wow!

“ Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace”

What did the Annovis CEO “showcase” that would drive the price down?

Is the company needing to raise more money again? If so then the drop makes sense.

Long on ANVS. Been holding and accumulating for about a year. I believe this company has a game changing drug for Parkinson’s and Alzheimer’s disease. Analyst target is $30. I believe it can go. Much higher.

Jmo
Loofman

Starter $7.90

$ANVS

Is that Chart of yours showing the nice squeeze play I saw or are my eyes deceiving me?

Or is it that it has been shorted to a point and now a reverse is in effect??? What’s your chart say???

Hmmmm. Has a deal announcement been leaked?????

ANVS under $10

$$$ANVS$$$ Conf on Weds could mean MONSTER WEEK AHEAD! $$$ GLTA

Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap

MALVERN, Pa.

July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to transition to a new solid form of buntanetap in future clinical trials.

In June 2024, Annovis announced the filing of a composition of matter patent for the new crystal form of buntanetap and a provisional patent for the manufacturing process of this new form. The Company conducted comprehensive bridge studies in various solvents and in animals, comparing the old semi-crystalline form with the new crystalline form of buntanetap. Additionally, Annovis developed an innovative large-scale manufacturing process for the new form. This comprehensive data was submitted to the FDA for review.

The FDA has now approved the continuation of buntanetap's development using the new crystal form. This positive response allows Annovis to conduct a comparative study between the old and new forms of buntanetap in a small, single-dose, bioavailability study in humans as part of the transition process.

Oh yeah!

$$$ANVS$$$ Glad I got mine!!! $$$

Agreed on the $20+ ANVS share price coming.

But if you want a Cancer Breakthrough treatment, take a look at RNAZ which has an extremely low OS if 6.6 million shares. They constantly get shorted same like ANVS does, but huge difference is the extremely low outstanding share count.

Hopefully we can see a cure for Parkinson’s, Alzheimer’s and cancer in short fashion. Good luck.

$ANVS look for continuation higher! 20.00+ coming.
Also loading breast cancer cure! $ICCM.
$ANVS

Isn't that the problem with almost every stock nowadays?
If it has to be,ANVS will succeed no matter the amount of shorting.
GLTY

The shorting is too strong. I'm concerned about getting back in.